Metraipolis › archive › dc_c0f482dbe702
Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-CD20 Monoclonal Antibodies for Multiple Sclerosis Treatment — Europe PMC PMID:40873276
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40873276
- DOI
- 10.2174/011570159x392955250815095236
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T06:32:02.714Z
- SHA-256 of the archived text
35a58774b80002e0af31969b590a6b0669507acf6da5e4be0dff6e21c76641ca- Stable URL of this page
https://metraipolis.com/documento/dc_c0f482dbe702
How to cite
Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-CD20 Monoclonal Antibodies for Multiple Sclerosis Treatment — Europe PMC PMID:40873276 — Europe PMC (en), https://europepmc.org/article/MED/40873276 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c0f482dbe702 (Metraipolis archive dc_c0f482dbe702, sha256 35a58774b80002e0af31969b590a6b0669507acf6da5e4be0dff6e21c76641ca)
BibTeX
@misc{dcc0f482dbe702,
title = {Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-CD20 Monoclonal Antibodies for Multiple Sclerosis Treatment — Europe PMC PMID:40873276},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40873276},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c0f482dbe702; sha256 35a58774b80002e0af31969b590a6b0669507acf6da5e4be0dff6e21c76641ca},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40873276. Agents can read the archived copy with the MCP tool read_document.